All In Biotech

Free tool

FAERS Monitor: Trudhesa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213436 or its brand name (Trudhesa, Dihydroergotamine Mesylate). Reports on generic versions are filed under their own applications.

Reports

1,336

Serious

685

51% of reports

Hospitalization

155

Death reported

21

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective591
  • nausea395
  • off label use367
  • hyperhidrosis356
  • nightmare339
  • sedation339
  • product use in unapproved indication293
  • nephrolithiasis252
  • migraine110
  • dyspnoea88
  • nasal congestion81
  • headache64
  • treatment failure58
  • diarrhoea52
  • dizziness51

Reports by year received

View as table
YearReports
200417
200516
200624
200724
200820
200915
201018
201126
201226
20132
20142
20152
20169
201718
201814
201926
202020
202167
2022172
2023237
2024181
2025181
2026219

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,823 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sedationSignal339206.4188.168,292
nightmareSignal339155.8142.051,549
nephrolithiasisSignal25287.077.821,258
hyperhidrosisSignal35643.639.914,835
nasal congestionSignal8121.717.61,583
product use in unapproved indicationSignal29318.616.84,924
migraineSignal11018.215.21,773
treatment failureSignal5811.08.6521
nauseaSignal3957.97.22,449
drug ineffectiveSignal5917.16.63,273
off label useSignal3676.66.01,813
dyspnoeaSignal882.42.076
dizziness511.61.211
headache641.61.315
diarrhoea521.31.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.